Knight Therapeutics Inc. (04K)

Overview

Knight Therapeutics Inc. is a distinguished entity in the pharmaceutical sector, specializing in the development, manufacturing, acquisition, licensing, marketing, and distribution of a broad range of pharmaceutical and consumer health products, as well as medical devices on a global scale. Since its inception in 2013, the company has consistently strived to address unmet medical needs by bringing innovative therapies to patients worldwide. With its headquarters located in Montreal, Canada, Knight Therapeutics Inc. not only focuses on delivering high-quality healthcare solutions but also engages in financing other life science companies and investing in life sciences venture capital funds, marking its significance and versatile role in the healthcare and pharmaceutical industries.

Products and Services

Knight Therapeutics Inc. offers an extensive portfolio of pharmaceutical products targeting a wide array of medical conditions. These include:

• Tafasitamab: Designed for patients with relapsed or refractory diffuse large B-cell lymphoma.
• Pemigatinib: A therapy for individuals battling metastatic cholangiocarcinoma.
• Akynzeo: A preventive measure for chemotherapy-induced acute and delayed nausea and vomiting.
• Aloxi: Aims to prevent acute nausea and vomiting associated with emetogenic cancer chemotherapy.
• Fostamatinib: Used in the treatment of chronic immune thrombocytopenia.
• Nerlynx: A medication for extended adjuvant breast cancer and metastatic breast cancer.
• Trelstar: Targets advanced prostate cancer with its therapeutic formula.
• Vidaza: A treatment option for myelodysplastic syndrome.
• Abraxane: An approved therapy for metastatic pancreatic cancer.
• Halaven: Utilized in treating metastatic breast cancer and soft tissue sarcoma.
• Lenvima: Offers treatment solutions for advanced renal cell cancer, differentiated thyroid cancer, and unresectable hepatocellular carcinoma.
• Other products encompass treatments for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, follicular lymphoma, metastatic prostate cancer, chronic myeloid leukemia, breast cancer, fungal infections, leishmaniasis, HIV infection, dementia, and irritable bowel syndrome with constipation.
• Additionally, Knight Therapeutics Inc. provides pharmaceutical solutions for ulcerative colitis, biliary cirrhosis, moderate to severe dyspareunia, vasomotor symptoms, idiopathic pulmonary fibrosis, pseudomonas aeruginosa lung infection, severe acute or resistant chronic infections, and chronic lung infections.